YPI 011 / KT&G Corp - LARVOL DELTA

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=88 | Completed | Sponsor: Yungjin Pharm. Co., Ltd. | Recruiting ➔ Completed

Trial completion • Gastroenterology • Gastroesophageal Reflux Disease

Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole. (PubMed, Drug Des Devel Ther) - "The PK-PD relationship of PPI is well known, and the faster absorption of rabeprazole resulted in a more rapid mode of action in acid suppression. The fixed dose combination of rabeprazole with NaHCO showed a faster absorption and consequently, a more rapid gastric acid suppression with a similar systemic exposure of rabeprazole at steady state compared to the conventional enteric-coated rabeprazole."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=88; Recruiting; Sponsor: Yungjin Pharm. Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastroenterology • Gastroesophageal Reflux Disease

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=88; Not yet recruiting; Sponsor: Yungjin Pharm. Co., Ltd.

Clinical • New P1 trial • Gastroenterology • Gastroesophageal Reflux Disease